Broad Spectrum of Interferon-related Nephropathies-glomerulonephritis, Systemic Lupus Erythematosus-like Syndrome and Thrombotic Microangiopathy: A Case Report and Review of Literature

Overview

Journal World J Nephrol

Publisher Baishideng Publishing Group

Specialty Nephrology

Date 2019 Nov 22

PMID 31750091

Citations 16

Authors

Iacopo Gianassi

Marco Allinovi

Leonardo Caroti

Lino Calogero Cirami

Affiliations

Soon will be listed here.

Abstract

Background: Interferons (IFNs) are characterized by a wide range of biological effects, which justifies their potential therapeutic use in several pathologies, but also elicit a wide array of adverse effects in almost every organ system. Among them, renal involvement is probably one of the most complex to identify.

Case Summary: We describe four cases of kidney damage caused by different IFN formulations: IFN-β-related thrombotic microangiopathy, IFN-β-induced systemic lupus erythematosus, and two cases of membranous nephropathy secondary to pegylated-IFN-α 2B. In each case, we carefully excluded any other possible cause of renal involvement. Once suspected as the casual relationship between drug and kidney damage, IFN treatment was immediately discontinued. In three cases, we observed a complete and persistent remission of clinical and laboratory abnormalities after IFN withdrawal, while the patient who developed thrombotic microangiopathy, despite IFN withdrawal and complement-inhibitor therapy with eculizumab, showed persistent severe renal failure requiring dialysis.

Conclusion: This case series highlights the causal relationship between IFN treatment and different types of renal involvement and enables us to delineate several peculiarities of this association.

Citing Articles

Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities.

Tumlin J, Rovin B, Anders H, Mysler E, Jayne D, Takeuchi T Kidney Int Rep. 2025; 10(1):29-39.

PMID: 39810777 PMC: 11725820. DOI: 10.1016/j.ekir.2024.10.013.

NET formation-mediated in situ protein delivery to the inflamed central nervous system.

Wu Y, Park J, Le Q, Byun J, Choi J, Xu E Nat Commun. 2024; 15(1):10747.

PMID: 39737919 PMC: 11686318. DOI: 10.1038/s41467-024-54817-7.

Therapeutically targeting proinflammatory type I interferons in systemic lupus erythematosus: efficacy and insufficiency with a specific focus on lupus nephritis.

Lai B, Luo S, Lai J Front Immunol. 2024; 15:1489205.

PMID: 39478861 PMC: 11521836. DOI: 10.3389/fimmu.2024.1489205.

Interferon-γ induces combined pyroptotic angiopathy and APOL1 expression in human kidney disease.

Juliar B, Stanaway I, Sano F, Fu H, Smith K, Akilesh S Cell Rep. 2024; 43(6):114310.

PMID: 38838223 PMC: 11216883. DOI: 10.1016/j.celrep.2024.114310.

Thrombotic Microangiopathy as a Life-Threatening Complication of Long-Term Interferon Beta Therapy for Multiple Sclerosis: Clinical Phenotype and Response to Treatment-A Literature Review.

Allinovi M, Mazzierli T, Laudicina S, Pasto L, Portaccio E, Amato M J Clin Med. 2024; 13(6).

PMID: 38541824 PMC: 10971339. DOI: 10.3390/jcm13061598.

References

Gordon A, Menahem S, Mitchell J, Jenkins P, Dowling J, Roberts S . Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy. Nephrol Dial Transplant. 2004; 19(8):2155. DOI: 10.1093/ndt/gfh336. View

Ubara Y, Hara S, Takedatu H, Katori H, Yamada K, Yoshihara K . Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis C. Nephron. 1998; 80(1):107-8. DOI: 10.1159/000045147. View

Markowitz G, Bomback A, Perazella M . Drug-induced glomerular disease: direct cellular injury. Clin J Am Soc Nephrol. 2015; 10(7):1291-9. PMC: 4491280. DOI: 10.2215/CJN.00860115. View

Vaglio A, Grayson P, Fenaroli P, Gianfreda D, Boccaletti V, Ghiggeri G . Drug-induced lupus: Traditional and new concepts. Autoimmun Rev. 2018; 17(9):912-918. DOI: 10.1016/j.autrev.2018.03.016. View

Fabrizi F, Aghemo A, Messa P . Hepatitis C treatment in patients with kidney disease. Kidney Int. 2013; 84(5):874-9. DOI: 10.1038/ki.2013.264. View

Miranda-Guardiola F, Fernandez-Llama P, Badia J, Botey A, Estruch R, Darnell A . Acute renal failure associated with alpha-interferon therapy for chronic hepatitis B. Nephrol Dial Transplant. 1995; 10(8):1441-3. View

Migliorini A, Angelotti M, Mulay S, Kulkarni O, Demleitner J, Dietrich A . The antiviral cytokines IFN-α and IFN-β modulate parietal epithelial cells and promote podocyte loss: implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration. Am J Pathol. 2013; 183(2):431-40. DOI: 10.1016/j.ajpath.2013.04.017. View

Tsai M, Chen J, Fang Y, Yang A, Chang C . Membranous nephropathy induced by pegylated interferon alpha-2a therapy for chronic viral hepatitis B. Clin Nephrol. 2012; 77(6):496-500. DOI: 10.5414/cn106903. View

Baechler E, Batliwalla F, Karypis G, Gaffney P, Ortmann W, Espe K . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003; 100(5):2610-5. PMC: 151388. DOI: 10.1073/pnas.0337679100. View

10.

GRESSER I . Biologic effects of interferons. J Invest Dermatol. 1990; 95(6 Suppl):66S-71S. DOI: 10.1111/1523-1747.ep12874776. View

11.

Kavanagh D, McGlasson S, Jury A, Williams J, Scolding N, Bellamy C . Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood. 2016; 128(24):2824-2833. PMC: 5159705. DOI: 10.1182/blood-2016-05-715987. View

12.

Conlon K, Urba W, Smith 2nd J, Steis R, Longo D, Clark J . Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer. 1990; 65(10):2237-42. DOI: 10.1002/1097-0142(19900515)65:10<2237::aid-cncr2820651013>3.0.co;2-5. View

13.

Morris L, Lemak N, Arnett Jr F, Jordon R, Duvic M . Systemic lupus erythematosus diagnosed during interferon alfa therapy. South Med J. 1996; 89(8):810-4. DOI: 10.1097/00007611-199608000-00012. View

14.

Jia H, Thelwell C, Dilger P, Bird C, Daniels S, Wadhwa M . Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy. Thromb Res. 2018; 163:105-116. DOI: 10.1016/j.thromres.2018.01.039. View

15.

Hunt D, Kavanagh D, Drummond I, Weller B, Bellamy C, Overell J . Thrombotic microangiopathy associated with interferon beta. N Engl J Med. 2014; 370(13):1270-1. PMC: 4066182. DOI: 10.1056/NEJMc1316118. View

16.

Allinovi M, Cirami C, Caroti L, Antognoli G, Farsetti S, Amato M . Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab. Clin Kidney J. 2017; 10(5):625-631. PMC: 5622889. DOI: 10.1093/ckj/sfw143. View

17.

Nishimura S, Miura H, Yamada H, Shinoda T, Kitamura S, Miura Y . Acute onset of nephrotic syndrome during interferon-alpha retreatment for chronic active hepatitis C. J Gastroenterol. 2002; 37(10):854-8. DOI: 10.1007/s005350200141. View

18.

Kundra A, Wang J . Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review. Crit Rev Oncol Hematol. 2017; 112:103-112. DOI: 10.1016/j.critrevonc.2017.02.011. View

19.

Graninger W, Hassfeld W, Pesau B, Machold K, Zielinski C, Smolen J . Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. J Rheumatol. 1991; 18(10):1621-2. View

20.

Dizer U, Beker C, Yavuz I, Ortatatli M, Ozguven V, Pahsa A . Minimal change disease in a patient receiving IFN-alpha therapy for chronic hepatitis C virus infection. J Interferon Cytokine Res. 2003; 23(1):51-4. DOI: 10.1089/10799900360520450. View